Objective: Several studies demonstrated that obese subjects have a hyperactive hypothalamic-pituitary-adrenal axis and that sex steroid hormones have been closely related to the regulation of adiposity, either through direct or indirect physiological mechanisms. Allopregnanolone (3a-hydroxy-5a-pregn-20-one; AP) is a circulating neuroactive steroid hormone involved in the modulation of behavioral functions, stress and neuroendocrine axis. The aim of our study was to evaluate basal serum AP levels in obese children. Subjects and measurements: We studied 27 normal weight (NW) and 23 overweight (OW) girls. Gonadotropins and steroid hormones were assessed in all patients. Results: Basal AP concentrations in OW girls were significantly higher than in NW controls (P ¼ 0.013). There was no difference found between the other gonadal and adrenal hormones. Considering the pubertal stage, we demonstrated that obese pubertal girls presented higher AP concentrations than prepubertal and pubertal NW ones (P ¼ 0.020), and higher dehydroepiandrosterone sulfate (DHEAS) levels with respect to prepubertal obese girls, and prepubertal and pubertal NW patients (P ¼ 0.025). AP and DHEAS were significantly directly related to weight (r ¼ 0.31 and r ¼ 0.54, respectively) and body mass index (r ¼ 0.29 and r ¼ 0.34, respectively). In pubertal OW girls, a significant positive correlation between AP and DHEAS (r ¼ 0.60), A (r ¼ 0.72) and luteinizing hormone (r ¼ 0.64) levels was demonstrated. Conclusion: The present study demonstrates that AP is hypersecreted in children and adolescent with OW involving DHEAS concentrations, too. Our data suggest a possible role of AP in the regulation of neuroendocrine axis related to obesity. We can also speculate that in OW girls, who could manifest emotional and behavioral problems, a part of higher levels of this neuroactive steroid might act as g-aminobutyric acid agonist producing anxiolytic-sedative effects.
Introduction
Several endocrine abnormalities are considered as causative factors for the development of obesity, whereas others are obesity-related alterations usually restored after weight loss.
The role of steroid hormones in obesity has been a controversial issue for many years. In obese Zucker rats, glucocorticoids seem to be important in the development of obesity, as adrenalectomy or glucocorticoid receptor antagonists reduce weight gain and associated metabolic abnormalities. 1 Until now, this relation was less well examined in children and adolescent. Increased adrenal androgen levels were demonstrated in obese children; 2,3 however, the underlying regulatory mechanism of their stimulation remains unknown. In adolescent girls, it has been shown that corticotropin-releasing hormone (CRH) 4 and insulin 5 were associated with higher androgen concentrations. Studies demonstrated that dehydroepiandrosterone sulfate (DHEAS) levels are correlated with adiposity, but the results are contrasting. So far, it has not yet been shown if in childhood and adolescence adrenal steroids and obesity are interrelated. 6, 7 The central nervous system (CNS) contains neuroactive steroids derived from periphery circulation. Neuroactive steroids are synthesized 'de novo' from cholesterol in the CNS, too. 8 Allopregnanolone (3a-hydroxy-5a-pregn-20-one; AP), the most important neuroactive steroid derived from pregnanolone, is an allosteric modulator of both g-aminobutyric acid A (GABA A ) and serotonin (5-HT 3 ) receptors, [9] [10] [11] and it is likely to possess sleep modulating, neuroprotective, anxiolytic, antidepressant and anticonvulsant properties. 11, 12 When administered to rats, AP suppresses the expression of vasopressin and CRH affecting the reproductive activity of the hypothalamic-pituitary-adrenal (HPA) system. 13, 14 Experimental data suggests that endogenous neuroactive steroids play an important role in the control of eating behavior. AP produces hyperphagic effects in food-deprived mice, whereas dehydroepiandrosterone (DHEA) and DHEAS induce hypophagia in hungry mice. 15, 16 Unlike AP's anxiolytic properties, little is known about which aspects of feeding are altered by AP to result in an increase in overall food consumption. It was suggested that AP significantly increase consummatory behaviors in the taste reactivity test, [17] [18] [19] [20] but it was also hypothesized that it significantly increase sucrose intake and licking by reducing anxiety associated with exposure to novel foods. 21 Increased serum levels of AP, DHEA and DHEAS were found in patients with eating disorders and these alterations were probably secondary to the overdrive of the HPA axis. 22, 23 Serum AP levels do not change during the first 2 years of life, but increase throughout puberty according to age and to the Tanner's stage, suggesting its possible role in the maturational process of hypothalamic-pituitary-gonadal (HPG) and HPA axes. Moreover, DHEA levels rise around 7 years of age and progressively increase, correlating positively with Tanner's stage. 24 The aim of this study was to assess basal neuroactive steroid concentrations in obese girls with respect to nonobese subjects, and to evaluate the role of these hormones as determining factors for obesity development.
Materials and methods

Subjects
Fifty girls aged 9.2171.89 years (range 6.00-15.00 years) were recruited for the study, randomly selected from outpatients of Pediatrics Endocrinology Unit of the University of Modena and Reggio Emilia. They were subdivided into two groups: group A, normal weight (NW) patients (n ¼ 27) aged 9.2871.55 years; group B, overweight (OW) subjects (n ¼ 23) aged 9.1272.26 years. Each group was subdivided into the following four groups on the basis of pubertal development: group A1, NW prepubertal girls (n ¼ 10) aged 8.3771.29 years; group A2, NW pubertal girls (n ¼ 17) aged 9.8271.47 years; group B1, OW prepubertal girls (n ¼ 12) aged 7.8871.24 years; and group B2, OW pubertal girls (n ¼ 11) aged 10.472.38 years. The clinical characteristics of the patients for each group are reported in Table 1 . None had acute or chronic diseases, and all endocrine diseases related to obesity were excluded. Patients with central or secondary precocious puberty and girls with polycystic ovary syndrome were excluded from the study. No pharmacological or dietary treatment was introduced before the hormonal investigation. Pubertal girls who were menstruating normally were tested during the follicular phase of their menstrual cycle (days 5-10 after the last menses). No subjects were taking oral contraceptives.
Methods
Body weight was measured to the nearest 0.1 kg and body height to the nearest 0.1 cm with a wall-mounted stadiometer (Harpenden, Crymych, UK).
We evaluated OW using IOTF/Cole BMI (body mass index) classification system. 25 The stages of pubertal development were determined using the grading system defined by Tanner for pubic hair and breast. 26 After an overnight fast, each subject underwent blood sample collection in the morning. An indwelling venous catheter was inserted into an antecubital vein and kept patent by a slow saline infusion, so that the same amount of fluid would be injected into each patient. Subjects rested supine for 30 min, and then blood was withdrawn for the assay of basal serum AP, DHEAS, androstenedione (A), 17 hydroxy-progesterone (17-OHP), cortisol, adrenocorticotropin hormone (ACTH), luteinizing hormone (LH), folliclestimulating hormone (FSH) and 17b-estradiol (E2). Blood samples for all hormones were centrifuged and serum was stored at À201C until assayed.
In all subjects, skeletal maturation was assessed on the basis of roentgenograms of the left hand and wrist. The radiographs were evaluated according to the method of Greulich and Pyle, 27 and bone age (BA) was determined. Allopregnanolone levels in overweight girls B Predieri et al LH and FSH assays. Serum LH and FSH concentrations were determined using a commercially available chemoluminescence assay kit (Bayer, Germany). The sensitivity of the assay was 0.07 mIU/ml for LH and 0.3 mIU/ml for FSH determinations. The intra-assay coefficients of variation (CV) was 4.9% for LH and 5.1% for FSH, whereas the inter-assay CV was 7% for both.
17-OHP and A assays. Serum 17-OHP and A were determined by radioimmunoassay (RIA) using the Coat-A-Count kit (DPC, Los Angeles, CA, USA). The sensitivity of the assay for 17-OHP was 0.1 ng/ml and the intra-and inter-assay CVs were 7.9 and 12%, respectively. For A the sensitivity of the assay was 10 ng/ml and the intra-and inter-assay CVs were 6.9 and 12%, respectively.
AP assay. AP concentrations were determined by an RIA as described previously. [28] [29] [30] H]pregnan-3a-ol-20-one (45 Ci/nmol) was purchased from Nen Life Science Products (Boston, MA, USA). The polyclonal antisera, raised in sheep against AP carboxymethyl ether coupled to BSA, were provided by Dr RH Purdy (San Diego, CA, USA). Serum samples after extraction and chromatographic partition were assayed using a previously described RIA method. 28 The sensitivity of the assay, expressed as a minimal amount of AP distinguishable from the zero sample with 95% probability, was 15 pg/ml, and the intra-and inter-assay CVs were 6.8 and 8.1%, respectively.
E2 and cortisol assays. Serum E2 and cortisol were determined, after extraction and chromatographic partition on C18 Sep-Pak cartridge, by RIA using a commercially available kit (Radim, Pomezia, Italy). The sensitivity of the assay was 10 pg/ml and the intra-and inter-assay CVs were 3.7 and 5.8%, respectively.
DHEAS assay. Serum samples for the determination of DHEAS were extracted with ether, purified through a C18 Sep-Pak cartridge and then assayed by RIA using a trade kit (DSL, Webster, TX, USA). The sensitivity was 15 pg/ml and the intra-and inter-assay CVs were 3.1 and 6.9%, respectively. The extraction and chromatography step was used for E2, cortisol and DHEAS to increase the reliability criteria of the specific methods.
ACTH assay. Plasma levels of ACTH were assayed using an RIA technique (ICN, Pharmaceutical, Orangeburg, NY, USA). The assay sensitivity was 9 pg/ml. The intra-and inter-assay CVs were 6.3 and 10.8%, respectively.
Statistical analysis
All results are presented as the mean7standard deviation (s.d.). Statistical analysis (STATISTICAt software, StatSoft Inc., Tulsa, OK, USA) was performed using Student's t-test for unpaired samples and analysis of variance (ANOVA) for comparison of hormone levels among the groups; Fisher least-squares difference (LSD) test was used to localize significant differences in group means in the analysis of variance. Pearson's correlation was also performed to analyze relationship among variables. Significance was set at Po0.05. ANOVA and Fisher LSD post hoc test showed that groups A1 and B1 were comparable for CA, BA and pubertal development; groups A2 and B2 were comparable for CA, BA and pubertal development, too. Compared with groups A1 and A2 patients, girls of both groups B1 and B2 had significantly higher BMI (Table 1) .
Results
Clinical data
Girls of groups A and B, evaluated using Student's t-test for unpaired samples, were comparable for chronological age
Biochemical data
Student's t-test for unpaired samples showed significantly higher serum levels of AP in girls of group B than in group A (0.7370.21 and 0.5970.17 nmol/l, respectively; P ¼ 0.013). No difference was found for the other hormone concentrations ( Table 2) .
The four groups, evaluated using ANOVA, demonstrated significant differences in serum concentrations of AP and DHEAS, but not in serum levels of A, 17-OHP, cortisol, ACTH, E2, LH and FSH (Table 3 ). In particular, LSD post hoc test showed that AP concentrations were significantly higher in group B2 respect to groups A1 and A2, but not B1 (0.8070.25, 0.5370.06, 0.6270.20 and 0.6770.15 nmol/l, respectively; P ¼ 0.020). DHEAS concentrations resulted higher in B2 girls than in A1, A2 and B1 ones (1.2871.05, 0.2970.20, 0.6970.56 and 0.5570.43 mg/ml, respectively; P ¼ 0.025).
When all girls were considered together, Pearson's correlation revealed that AP was significantly related with weight (r ¼ 0. Considering OW girls, using Pearson's correlation, we observed a positive relationship between AP and DHEAS (r ¼ 0.60), A (r ¼ 0.72) and LH (r ¼ 0.64) levels only in pubertal subjects (Po0.05), whereas no significant correlation was shown between cortisol and ACTH concentrations and other hormones.
Discussion
This is the first study assessing the secretion of AP in obese girls and we report here increased plasma concentrations of this neuroactive steroid. Considering that AP levels increase throughout pubertal development according to age and Tanner's stage, 24 in this study we showed that its levels were significantly higher in pubertal obese girls respect to prepubertal and pubertal non-obese ones, whereas no difference was demonstrated with prepubertal obese subjects. Our data demonstrating higher AP concentrations in pubertal obese girls than in pubertal non-obese ones suggest a possible relation between OW and this neuroactive steroid. The mechanisms underlying such an effect are not clear. Neuroactive steroids have been shown to influence the brain and in particular they can influence neurotransmitters involved in anxiety. Evidence that AP has anxiolytic properties in different animal models 31, 32 has suggested that alterations of neuroactive steroid secretion might be implicated in the pathogenetic mechanisms of anxiety disorders in humans. There are few data on neuroactive steroid secretion in anxiety disorders. Post-menopausal women with depression and anxiety had significantly lower concentrations of DHEA and of its derivative respect to asymptomatic subjects. These data suggest that neuroactive steroid could have a role in preventing the expression of anxiety. 33 Increased levels of progesterone, AP, tetrahydrodeoxycorticosterone and pregnanolone were found in female patients with panic disorder, suggesting that neuroactive steroids with anxiolytic activity increase as a homeostatic mechanism to counteract the underlying hyperactivity of the HPA axis. 34 There is a common belief that OW children are unhappy with their weight and experience more psychosocial distress, particularly depressive symptoms. 35, 36 Based on the existing literature with adolescent and adult samples, body fatness and depressive symptoms would be modesty associated, and this association would be stronger for girls than for boys. It has been hypothesized that preadolescent girls develop more risk factors for depression than boys do and that these risk factors lead to depression in early adolescence. 35 Recently, in Allopregnanolone levels in overweight girls B Predieri et al females anxiety disorders and depression were demonstrated to be associated with higher BMI z-score, whereas these disorders in males were not substantively associated with weight status. 37 Psychological problems are important consequences of OW or obesity, but it might be really important to understand whether psychological stress triggers obesity or whether it is the early HPA hormone secretion that leads to psychosocial problems. It is possible that the increased production of AP demonstrated in our obese girls represent an adaptive phenomenon to contrast the enhanced levels of psychological distress and anxiety among these patients. DHEA and DHEAS are involved in the regulation of neuronal survival and differentiation and in the modulation of cognitive functions, mood and a sense of well-being, likely through an action on brain 5-HT 3 , GABA A and glutamate transmission.
11 Actually, the relationship between DHEAS and cognitive function and various physical health outcomes is unclear and the underlying mechanisms remain speculative.
38
DHEAS levels increase according to age and pubertal stage. 24 In our study, we demonstrated that its levels were significantly higher in pubertal obese girls than in other groups suggesting, as well as AP, a possible role of this neuroactive steroid in mechanisms determining obesity and its related psychological problems. Several studies demonstrated that DHEAS levels are correlated with adiposity, but the results are contrasting. 7 In female mice, subchronic treatment with DHEAS for 28 days produced significant decreases in body weight and food intake 39 and another study suggests that maintaining high levels of DHEAS might prevent the development of obesity. 40 The major source of blood DHEAS is the adrenal gland and its secretion is regulated by the CRH/ACTH axis. There is evidence that this axis is hyperactive in obese subjects causing the increase of neuroactive steroids level. Hyperresponsiveness of the HPA axis to CRH tests or to stress has been shown in obese subjects with ACTH responses significantly higher than in controls. 41, 42 In our study, only AP and DHEAS levels resulted different between studied groups and in pubertal OW girls were positively correlated, whereas for the other steroid hormones no differences were found. In agreement with previous reports, in both our prepubertal and pubertal obese girls, serum cortisol concentrations were not significantly different from their control groups, and no correlation was demonstrated with other hormones. The relationship between adrenal secretion and obesity remains unclear, as increased basal cortisol secretion was also reported in obese subjects. 42, 43 Although a single morning measurement of serum cortisol (such as all the other hormones with a known circadian rhythm) is not representative of the circadian activity of the HPA axis, the finding of normal morning cortisol levels suggests that changes in DHEAS in our pubertal obese girls were not owing to an overactive CRH/ACTH system, prompting a dissociation in the adrenal secretion of DHEAS and cortisol.
Previous studies demonstrated that obese patients have higher basal AP levels than controls, even in the presence of unchanged cortisol levels. In obese patients, after CRH administration, the secretory incremental area of AP was significantly higher than in controls, whereas CRH injection increased cortisol levels in both obese and control subjects to a comparable extent. These data suggest both peripheral sources of this neuroactive steroid and different regulatory mechanisms involved in the secretion of AP and cortisol by the adrenal gland. 43 Unconjugated steroids are liposolubles, hence bloodcirculating levels should correspond with those in the CNS. However, certain brain regions are endowed with high levels of steroidogenic enzymes 44 setting the possibility for dissociated levels between plasma and brain levels. The difficulty to distinguish the amount of neuroactive steroids secreted centrally or peripherally represents a bias of our research. However, we demonstrated that in pubertal obese girls AP was significantly higher than in pubertal non-obese ones, and being both gonads and adrenal glands sources of this neuroactive steroid, its higher levels in obese subjects suggest that adrenals may represents the major source. In this study, considering all patients, we found that both AP and DHEAS were positively correlated with weight and BMI, strongly suggesting a possible role of these neuroactive steroids in the mechanisms involved in weight gain. The biological significance of increased circulating AP concentrations is not yet known. However, as neuroactive steroids are able to modulate feeding behavior in rats, a species in which AP has hyperphagic effects, 45, 46 hypersecretion of AP observed in our patients may represent one of the mechanisms underlying obesity. A recent study demonstrated that AP-induced hyperphagia, selective for safe and palatable foods, is likely owing to reduction of the anxiety associated with exposure to new foods without altering food palatability. 47 In our pubertal obese girls, the elevation of AP and DHEAS may represent an adaptive phenomenon that occurs to antagonize the potentially deleterious behavioral and metabolic effects of HPA hyperactivity or to decrease the anxiety related to foods. Because we did not rate anxiety levels in our girls, this hypothesis remains to be proved in future studies.
